

# Agenda | Day 1 | The Insight Day - Nordic Companies Wednesday 28 November 2018

Venue: Shearman & Sterling, 599 Lexington Avenue, New York, NY 10023

---

From 8:30 Registration & Breakfast

9:00 Welcome Address

9:15-10:00 **Financing Options for Early and Mid-Stage Companies**

**Moderator:** Mark Kessel, Co-Head of the Healthcare Group and Of Counsel, Shearman & Sterling

**Panelists:**

**Rob Masella**, Co-Head of the Healthcare Group and Partner, M&A, **Shearman &**

**Björn Bjerke**, Partner, Finance, **Shearman & Sterling**

**Vasilios Kofitsas**, Senior Director, Financial Advisory, **Back Bay Life Science Advisors**

10:00-10:15 *Break*

10:15-11:00 **Experience and Insights on the FDA Regulatory Process**

**Moderator:** Michelle Hoffmann, PhD, Back Bay Life Science Advisors, Senior VP

**Panelists:**

**William Gannon**, MD, Chief Scientific Officer & Medical Director,

**Capital City Technical**

**Olli Keränen**, CEO and Founder, **Medtentia**

**Kim Raymer**, VP Regulatory Affairs, **Halloran Consulting**

**Soren Dahl**, CEO, **Prophylix**

11:00-11:45 **Characteristics of the Effective Board member – Management & Investor Perspectives**

**Moderator:** Jonathan P. Gertler, MD, Back Bay Life Science Advisors, Managing Director CEO, Back Bay HealthCare Capital, Managing Partner

**Panelists:**

**Steve Israel**, Vice Chairman Biotechnology & Pharmaceuticals, **Korn Ferry**

**Greg Brown, M.D.**, Advisory Board Chair, **Back Bay HealthCare Capital**

**Mark Leuchtenberger**, Interim CEO, **Brooklyn ImmunoTherapeutics**

11:45-12:15 *Keynote Speaker & Networking Lunch*

12:15-12:45 **Keynote Speaker: Agam Sheth, PhD,**

Director, Business Development and Licensing, **Merck & Co**

12:45-13:00 *Break*

13:00-13:45 **Trends and Direction of U.S. Pricing and Reimbursement**

**Moderator:** Michelle Hoffmann, PhD, Back Bay Life Science Advisors, Senior VP

**Panelists:**

**Cybele Bjorklund**, Distinguished Visitor at the O'Neill Institute for National and

Global Health Law at **Georgetown University's Law Center**

**Peter Bak**, PhD, Vice President, **Back Bay Life Science Advisors**

**Arthur Hiller**, CEO, **Antyllus Therapeutics, Inc.**

**Calli Merkel, PhD**, Associate Director - Market Access, **Alnylam Pharmaceuticals**

13:45-14:15 **IPOs and Public Companies – Current Issues & Legal Considerations**

**Doreen Lilienfeld**, Co-Head of the Healthcare Group and Global Head

of the Governance & Advisory Group, **Sherman & Sterling**

**Lona Nallengara**, Partner, Capital Markets, **Shearman & Sterling**

14:15-14:45 **Investor Relations Considerations in Advance of a NASDAQ IPO**

**Lilian Stern**, Principal, **Stern IR**

**Hannah Deresiewicz**, Senior Associate, **Stern IR**

*Continue on next page*

14:45 *Closing Remarks*

14:50 **Walk to Nasdaq** - 4 Times Square, Nasdaq, New York, NY 10036, USA

15:15-16:30 **Going Public and Nasdaq Stock Market Closing Bell Ceremony**  
(By Invitation: Nordic Companies and Partners)

**Panelists:**

**Thomas Tangen**, Head of Healthcare Banking, **DNB**

**Carsten Borring**, Head of Listing & Capital Markets Denmark, **Nasdaq**

**Peter Legind-Hansen**, Managing Director, **Nasdaq**

17:00 *End-of-day Reception & Networking*  
The Swedish Residence, The Swedish Consulate General in New York

# Agenda | Day 2 | Listed Company Day Thursday 29 November 2018

Venue: 10 on the Park, 60 Columbus Circle, New York, NY 10019

From 07:30 Registration & Breakfast

From 08:30 1x1 meetings will be held in the Hudson and Tower Room

- From** **Columbus Room**  
8:15 *Opening Remarks by DNB / Nasdaq*
- Special Guest Foreword: Annika Rembe**  
Consul General of Sweden in New York, "The Life Science Ecosystem in Sweden"
- 830 **Bactiguard**, Christian Kinch (CEO) or Cecilia Edstrom (CFO)  
845 **Sedana Medical**, Christer Ahlberg (CEO)  
900 **Ossur**, Sveinn Solvason (CFO)  
915 **Biotage**, Erika Soderberg Johnson (CFO)  
930 **Ambea**, Fredrik Gren (CEO)
- 945 *Coffee Break*
- 1000 **Trends in Nordic Medtech: Denmark-Norway-Finland-Sweden**  
Moderator: Rune Dahl, Healthcare Research Analyst, DNB Markets  
**Panelists:**  
Val Kratzman, Director of Healthcare, **Business**  
Kathrine Myhre, CEO, **Norway Health Tech**  
Iris Ohrn, Life Science Investment Advisor, **Business Region Goteborg AB**  
Etienne Adriansen, Deputy Director, **Healthcare Denmark**
- 1030 **BerGenBio**, Richard S. Godfrey (CEO)  
1045 **Recipharm**, Thomas Eldered (CEO)  
1100 **XBrane Biopharma**, Martin Åmark (CEO)  
1115 **Karolinska Development**, Viktor Drvota (CEO)  
1130 **Alligator**, Per Norlen (CEO)  
1145 **Isofol Medical**, Anders Rabbe (CEO)
- 1200 *Lunch*
- 12:30 **Keynote Panel**  
**The Allure and Challenges of Nordic Healthcare Acquisitions and Partnerships**  
Moderator: Jim Cirenza, Managing Director, DNB Markets
- Special Guest Foreword: Harriet Berg**, Norway Consul General  
*Norwegian Business Environment Update*
- Keynote Panelists:**  
Prasanna Thombre, VP Global Treasury, **Alexion**  
Jonathan Gertler, MD, CEO & Managing Director, **Back Bay Life**  
Edwin Klumper, CEO, **Lytix Biopharma**  
Oystein Soug, CEO, **Targovax**
- 1300 **Private Company Track**  
Moderator: Jonathan Gertler, MD  
CEO & Managing Director, **Back Bay Life Science Advisors**
- Alzinova** - Per Wester (CEO)  
**Cellink** - Gusten Danielsson (CFO)  
**Cytovac** - Kim Arvid Nielsen (CEO)  
**Genetic Analysis** - Emilie Lasson (Chief Commercial Officer)  
**Inven2** - Ole Kristian Hjelstuen (CEO)  
**Lytix Biopharma** - Edwin Klumper (CEO)  
**Medtentia** - Olli Karanen (Founder & CEO)  
**Modus Therapeutics** - Ellen Donnelly (CEO)  
**Umecrine Cognition** - Magnus Doverskog (CEO)

Continue on next page

1430 **Infant Bacterial Therapeutics**, Staffan Stromberg (CEO)  
1445 **Photocure**, Daniel Schneider (President & CEO)  
1500 **Targovax, Oystein Soug (CEO)**  
1515 **Alk-Abello**, Per Plotnikof (VP Corporate Communication & IR)  
1530 **Moberg Pharma**, Peter Wolpert (CEO)  
1545 **Orexo**, Robert DeLuca (President Orexo US Inc)  
1600 **Herantis Pharma**, Pekka Simula (CEO)  
1615 **Cline Scientific**, Patrik Sundh (President, CEO & Co-founder)  
1630 **Cereno Scientific**, Sten Sorensen (CEO)

*From 1645 Closing Remarks and Conference Reception*